Search
Dactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalA compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termina...
Synonyms: ACTINOMYCIN X1, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamideCategories: P-glycoprotein inhibitors, P-glycoprotein substratesDipyridamole
go.drugbank.com/drugs/DB00975ApprovedInvestigationalA phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 199...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: PERSANTIN INJECTION 10 mg/2 ml, DIPIRIDAMOLMAX VISION(SOLUCION INYECTABLE 5MG/ML)Ethinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigationalEthinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitu...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: NAVEENFrovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLevobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnLevobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the t...
Synonyms: L-BUPIVACAINE, L-(−)-bupivacaineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBusulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalBusulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (my...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: BUSULFAN SOLUCIÓN INYECTABLE 60 MG/10 ML, BUSULTU 6 MG/ML IV İNFÜZYON İÇİN KONSANTRE ÇÖZELTİ, 1 ADETMetyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Categories: Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP3A InducersGlyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigationalGlyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin se...
Synonyms: 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylureaCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPhylloquinone
go.drugbank.com/drugs/DB01022ApprovedInvestigational[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X. … [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity
Mixtures: L-SOLUVIT NProducts: /ML., Vitamin K1 Inj 2mg/mlFelodipine
go.drugbank.com/drugs/DB01023ApprovedIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: FELODIPIN AL 5MG RETARD, FELODIPIN AL 10MG RETARD